L1 Technology Package for Diagnosis & Therapy of Ovarian and Endometrial Cancer
L1 is overexpressed in highly malignant carcinomas and human ovarian tumors. The antibody 9.3 has improved anti-tumor capacities by inhibit tumor growth and invasion of tumor cells. Antibody can be also used to determine the L1 level in a patient.
Further information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
As Germany's association of technology- and patenttransfer agencies TechnologieAllianz e.V. is offering businesses access to the entire range of innovative research results of almost all German universities and numerous non-university research institutions. More than 2000 technology offers of 14 branches are beeing made accessable to businesses in order to assure your advance on the market. At www.technologieallianz.de a free, fast and non-bureaucratic access to all further offers of the German research landscape is offered to our members aiming to sucessfully transfer technologies.
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Compact LCOS Microdisplay with Fast CMOS Backplane
…for High-Speed Light Modulation. Researchers from the Fraunhofer Institute for Photonic Microsystems IPMS, in collaboration with HOLOEYE Photonics AG, have developed a compact LCOS microdisplay with high refresh rates that…
New perspectives for material detection
CRC MARIE enters third funding period: A major success for terahertz research: Scientists at the University of Duisburg-Essen and the Ruhr University Bochum have been researching mobile material detection since…
CD Laboratory at TU Graz Researches New Semiconductor Materials
Using energy- and resource-saving methods, a research team at the Institute of Inorganic Chemistry at TU Graz aims to produce high-quality doped silicon layers for the electronics and solar industries….